This trial is testing a new drug for brain cancer that has progressed during first or second line treatment.
1 Primary · 3 Secondary · Reporting Duration: 1 year
34 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · N/A
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: